The Clomipramine Shortage: A Provider-Focused Update for 2026

The intermittent shortage of Clomipramine (brand name Anafranil) continues to affect patients and prescribers across the United States. For clinicians who treat obsessive-compulsive disorder, this shortage presents both logistical and clinical challenges — from helping patients locate their medication to managing medication transitions when supply is simply unavailable.

This article provides a clinical overview of the current shortage, evidence-based guidance on alternatives, and practical tools to help your patients maintain treatment continuity.

Current Shortage Status

Clomipramine has experienced intermittent supply disruptions since approximately 2020. As of early 2026:

• Generic Clomipramine remains available but inconsistently stocked across the US
• Brand-name Anafranil is largely discontinued in the US market
• The 50 mg and 75 mg capsule strengths have been most commonly affected, though shortages can shift across strengths unpredictably
• No firm resolution date has been published by the FDA or ASHP
• Multiple generic manufacturers (including Mallinckrodt and Taro) continue production, but output has not fully met demand

For a patient-facing overview of the shortage, see our patient shortage update.

Clinical Significance for OCD Patients

Clomipramine holds a unique position in OCD pharmacotherapy. It is the only tricyclic antidepressant FDA-approved for OCD and has been a mainstay of treatment for over three decades. Key clinical considerations:

• Efficacy: Meta-analyses have suggested Clomipramine may have a slight efficacy advantage over SSRIs in OCD, though head-to-head trials show mixed results. For patients with treatment-resistant OCD who have failed multiple SSRIs, Clomipramine is often the next-line agent.
• Patient population: Many patients currently on Clomipramine have specifically failed or not tolerated SSRIs. For these patients, a shortage-driven medication switch can be clinically destabilizing.
• Discontinuation risk: Abrupt discontinuation of Clomipramine can cause cholinergic rebound, withdrawal symptoms (nausea, headache, malaise, sleep disturbance), and rapid OCD symptom recurrence. Patients who cannot fill their prescription face real medical risk.

Helping Patients Locate Clomipramine

Before transitioning patients to an alternative, exhaust efforts to locate Clomipramine. Several strategies can help:

Real-Time Pharmacy Inventory Tools

Medfinder for Providers offers real-time pharmacy inventory data that can help you direct patients to pharmacies with current Clomipramine stock. This can reduce the burden on your office staff and improve the patient experience during a stressful time.

Dose Flexibility

Consider whether the patient's dose can be achieved with a different combination of available strengths. Clomipramine is available in 25 mg, 50 mg, and 75 mg capsules. For example:

• A patient on 150 mg/day taking two 75 mg capsules could switch to three 50 mg capsules or six 25 mg capsules
• A patient on 200 mg/day could combine 75 mg + 50 mg + 75 mg capsules

Rewriting the prescription for a different capsule strength may be all that is needed to bridge a gap.

Compounding Pharmacies

For patients who cannot find commercially manufactured Clomipramine in any strength, compounding pharmacies can prepare it from raw ingredients. This requires a prescription specifically written for the compounding pharmacy and typically costs more, but it can prevent treatment interruption.

90-Day Prescriptions

Where insurance allows, consider writing for 90-day supplies. This reduces the frequency of refill-related disruptions and gives patients a larger buffer. Pre-authorize with insurers as needed.

When a Switch Is Necessary: Evidence-Based Alternatives

If Clomipramine is truly unavailable and the patient cannot wait, the following alternatives have the strongest evidence base for OCD:

First-Line Alternatives: SSRIs

All four SSRIs below are FDA-approved for OCD and supported by robust clinical trial data:

Switching Protocols

Cross-tapering from Clomipramine to an SSRI requires care due to the risk of serotonin syndrome during overlap periods. General principles:

• Gradual taper: Reduce Clomipramine by 25 mg every 3 to 7 days. The rate depends on the patient's current dose, duration of treatment, and sensitivity to discontinuation.
• Wash-out considerations: Clomipramine has a half-life of approximately 32 hours (desmethylclomipramine: ~69 hours). A brief wash-out period (3 to 5 days at the lower dose) before initiating the SSRI can reduce serotonin syndrome risk.
• SSRI initiation: Start the SSRI at a low dose and titrate according to standard protocols. Inform the patient that full OCD response may take 8 to 12 weeks.
• Monitoring: Schedule follow-up at 1, 2, 4, and 8 weeks post-switch. Monitor for discontinuation symptoms, serotonin syndrome signs, and OCD symptom changes.
• Document: Note in the chart that the switch was necessitated by a supply shortage, not clinical failure. This is important for insurance purposes and future treatment decisions.

Augmentation and Combination Strategies

For patients with partial SSRI response who were using Clomipramine specifically because SSRIs were insufficient, consider:

• Low-dose Clomipramine augmentation (25–50 mg) added to an SSRI — requires careful monitoring for serotonin syndrome and Clomipramine level changes due to CYP interactions
• Augmentation with low-dose aripiprazole (2–10 mg) or risperidone (0.5–2 mg)
• Referral for ERP therapy (exposure and response prevention) as an adjunct
• Consideration of memantine, N-acetyl cysteine, or ondansetron as experimental adjuncts in refractory cases

Communication and Documentation Best Practices

The shortage creates administrative burden. Here are recommendations:

• Prior authorization: If switching to an alternative requires PA, include documentation that the switch is shortage-driven. Many insurers have expedited processes for shortage-related changes.
• Patient education: Direct patients to reliable resources. Our patient-facing posts on alternatives to Anafranil and finding Anafranil in stock can supplement your in-office counseling.
• Proactive outreach: Consider identifying patients on Clomipramine in your panel and proactively reaching out before they run out. A 10-minute phone call can prevent a crisis.
• Pharmacy coordination: Establish communication channels with local pharmacies. Some will notify your office when Clomipramine arrives in stock.

Tools for Providers

Medfinder for Providers is a free tool that helps clinicians and their staff locate medications affected by shortages. You can search by medication and location to find pharmacies with current stock, saving time for both your practice and your patients.

For additional provider resources, see our companion article on how to help your patients find Anafranil in stock.

Looking Ahead

The Clomipramine shortage reflects broader structural issues in the generic pharmaceutical supply chain — limited manufacturers, thin margins, and fragile global sourcing. While there are signs that some manufacturers are working to increase production, there is no guaranteed resolution timeline.

In the meantime, prescribers play a critical role in ensuring treatment continuity. By staying informed, using available tools, and proactively managing transitions, you can help your patients navigate this shortage with minimal clinical disruption.

We will update this article as new information becomes available. For patient-facing resources, direct your patients to medfinder.com.